Injectable drug‑releasing bone cement for bone metastases
Next generation anti-cancer drugdelivering cement for bone metastasis patients
An injectable bone cement that slowly releases cancer medicine and helps rebuild damaged bone for people whose cancer has spread to their bones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curer INC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11177833 on NIH RePORTER |
What this research studies
This project is making a new injectable bone cement you could receive at the site of bone damage caused by metastatic cancer. The cement is designed to hold and release anti-cancer drugs locally, while using calcium‑based materials that support bone healing rather than just acting like plexiglass. The goal is to stabilize weakened bone, reduce pain and fractures, and provide local cancer control in a minimally invasive procedure. Developers plan to replace current PMMA cements with a formulation that both treats tumor cells and promotes bone regeneration.
Who could benefit from this research
Good fit: People with cancer that has spread to bone causing bone loss, pain, or fractures and who are candidates for a minimally invasive cement injection procedure would be ideal candidates.
Not a fit: People without bone metastases, those with widely uncontrolled systemic disease not helped by local treatment, or individuals ineligible for injection procedures (or allergic to cement components) may not benefit.
Why it matters
Potential benefit: If successful, the cement could shrink local bone tumors, help bone heal, lower fracture risk and pain, and improve quality of life for people with bone metastases.
How similar studies have performed: Drug‑loaded and calcium phosphate cements have been used for bone repair and local drug delivery, but a safe, effective injectable cement specifically designed to kill metastatic cancer cells while regenerating bone is still relatively novel.
Where this research is happening
Cambridge, United States
- Curer INC — Cambridge, United States (Active)
Researchers
- Principal investigator: Jang, Hae Lin — Curer INC
- Study coordinator: Jang, Hae Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.